Tempest Therapeutics
$1.64
117
+$0.12+7.89% Tuesday 20:00
Statistics
Day High
1.66
Day Low
1.5
52W High
12.23
52W Low
1.5
Volume
177,968
Avg. Volume
143,836
Mkt Cap
7.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
30MarExpected
Expected EPS
-0.62
Actual EPS
-0.62
Financials
-Profit Margin
Unprofitable0Revenue
-83.69MNet Income
Analyst Ratings
$11.00Average Price Target
The highest estimate is 11.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TPST. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Merck
MRK
Mkt Cap214.76B
Pfizer
PFE
Mkt Cap140.15B
Gilead Sciences
GILD
Mkt Cap148.78B
AMGEN
AMGN
Mkt Cap160.66B
Novartis
NVS
Mkt Cap237.61B
Roche
RHHBY
Mkt Cap258.9B
Astrazeneca
AZN
Mkt Cap256.58B
Johnson & Johnson
JNJ
Mkt Cap455.04B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
About
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Show more...
CEO
Mr. Stephen R. Brady J.D., LLM
Employees
24
Country
US
ISIN
US87978U2078
Listings
0 Comments
Share your thoughts
FAQ
What is Tempest Therapeutics stock price today?▼
The current price of TPST is $1.64 USD — it has increased by +7.89% in the past 24 hours. Watch Tempest Therapeutics stock price performance more closely on the chart.
What is Tempest Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tempest Therapeutics stocks are traded under the ticker TPST.
Is Tempest Therapeutics stock price growing?▼
TPST stock has fallen by -5.75% compared to the previous week, the month change is a -28.07% fall, over the last year Tempest Therapeutics has showed a +358.74% increase.
What is Tempest Therapeutics market cap?▼
Today Tempest Therapeutics has the market capitalization of 7.28M
What were Tempest Therapeutics earnings last quarter?▼
TPST earnings for the last quarter are -0.62 USD per share, whereas the estimation was -0.62 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tempest Therapeutics revenue for the last year?▼
Tempest Therapeutics revenue for the last year amounts to 0 USD.
What is Tempest Therapeutics net income for the last year?▼
TPST net income for the last year is -83.69M USD.
How many employees does Tempest Therapeutics have?▼
As of April 01, 2026, the company has 24 employees.
In which sector is Tempest Therapeutics located?▼
Tempest Therapeutics operates in the Health Care sector.
When did Tempest Therapeutics complete a stock split?▼
The last stock split for Tempest Therapeutics was on January 30, 2026 with a ratio of 2:1.
Where is Tempest Therapeutics headquartered?▼
Tempest Therapeutics is headquartered in Brisbane, US.